Blueprint Medicines Corp. (BPMC) saw its stock plummet 8.27% in pre-market trading on Thursday, after the company reported its fourth-quarter and full-year 2024 financial results.
The biopharmaceutical company, focused on developing treatments for cancer and rare diseases, reported mixed results for the quarter:
For the full year 2024, Blueprint Medicines reported:
The company provided guidance for 2025, anticipating global AYVAKIT net product revenue of approximately $680 million to $710 million, representing 45% year-over-year growth at the midpoint.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.